FDA approves Novartis’ Itvisma gene therapy for SMABy jay.trebleDecember 4, 2025Listen to this article The basics: FDA approves Novartis‘ Itvisma as first gene replacement therapy for SMA patients age 2+ Treatment targets the SMN1 gene mutation,…
3
4
5
